Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00126139|
Recruitment Status : Terminated (Higher hemorrhage rates of Abciximab in ABESST II trial)
First Posted : August 2, 2005
Last Update Posted : May 3, 2007
|Condition or disease||Intervention/treatment||Phase|
|Stroke Stenosis||Drug: Abciximab||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Abciximab Versus Aspirin for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic >50% Carotid Stenosis: A Pilot Study (ASTERICS)|
|Study Start Date :||April 2004|
|Actual Study Completion Date :||May 2005|
- Whether abciximab compared with aspirin reduces the rate of recurrent ischemic strokes in territory of symptomatic carotid artery during administration of study drug, preoperative period or carotid endarterectomy
- Reduction of the degree of carotid stenosis at ultrasound studies performed 48-72 h after compared to 24 h prior to iv administration of the study agents.
- Reduction of MES counts measured 48-72 h after compared to 24 h prior to the administration of the iv study drugs.
- Difference of number of acute ischemic infarct on DWI assessed 48-72 h after compared to 24 h prior to the administration of the iv study drugs.
- Symptomatic ICH and asymptomatic hemorrhagic transformation occurring during or within 48-72 h after the administration of the iv study drugs.
- Size of plaque/intraplaque thrombus and intraplaque hemorrhage will be assessed at pathological examination of endarterectomy specimen after CEA.
- Clinical outcome at 90 days will be assessed using the NIHSS and the mRS.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00126139
|University of Basel, Department of Neurology|
|Basel, Switzerland, 4031|
|University of Bern, Department of Neurology|
|Bern, Switzerland, 3010|
|University of Geneva, Department of Neurology|
|Geneva, Switzerland, 1211|
|University of Lausanne, Department of Neurology|
|Lausanne, Switzerland, 1011|
|University of Zurich, Department of Neurology|
|Zurich, Switzerland, 8091|
|Study Chair:||Ralf W. Baumgartner, MD||University Hospital of Zurich, Department of Neurology, Switzerland|